Moguisteine

Moguisteine is a cough suppressant or antitussive that was discovered in the 1980s. It is a non-narcotic medication, meaning it does not have the potential for misuse that some other cough suppressants do. Moguisteine works by reducing the activity of the cough center in the brain, which can decrease the urge to cough.

History

Moguisteine was first synthesized in the 1980s by a team of researchers at the Mogu Pharmaceuticals company. The team was searching for a new, non-narcotic cough suppressant that would be effective without the risk of misuse or addiction. After extensive testing, they discovered moguisteine, which showed promise in both animal and human trials.

Pharmacology

Moguisteine is a peripheral antitussive, which means it works by reducing the activity of the cough center in the brain. This can decrease the urge to cough, making it useful for treating conditions such as chronic bronchitis and cough variant asthma.

Moguisteine is metabolized in the liver and excreted in the urine. It has a half-life of about 2-3 hours, which means it needs to be taken several times a day to maintain its effect.

Side Effects

Like all medications, moguisteine can cause side effects. These can include nausea, vomiting, dizziness, and drowsiness. In rare cases, it can cause more serious side effects such as allergic reactions or respiratory depression.

Availability

Moguisteine is available in many countries around the world, including Japan, South Korea, and several countries in Europe. However, it is not currently approved for use in the United States.

See Also

• Cough suppressant
• Antitussive
• Chronic bronchitis
• Cough variant asthma

Moguisteine Resources
Latest articles Most recent articles Ongoing trials	Wikipedia